Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2013 - 2026)
Larimar Therapeutics (LRMR) reported Net Income towards Common Stockholders of -$32.78 million for Q2 2026, compared with -$26.18 million a year earlier.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Larimar Therapeutics' Net Income towards Common Stockholders came in at -$169.18 million; for FY2025, it came in at -$165.7 million.
- By year, Net Income towards Common Stockholders came in at -$80.6 million in FY2024, -$36.95 million in FY2023, -$35.4 million in FY2022 and -$50.64 million in FY2021.
- Five-year quarterly Net Income towards Common Stockholders spans a low of -$62.5 million in Q4 2025 and a high of -$6.53 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Larimar Therapeutics | 307.49 Mn | -299.58 Mn | - | -32.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.78 Mn |
| Dec 31, 2025 | -62.50 Mn |
| Sep 30, 2025 | -47.71 Mn |
| Jun 30, 2025 | -26.18 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Dec 31, 2024 | -28.80 Mn |
| Sep 30, 2024 | -15.50 Mn |
| Jun 30, 2024 | -21.63 Mn |
| Mar 31, 2024 | -14.65 Mn |
| Dec 31, 2023 | -12.95 Mn |
| Sep 30, 2023 | -9.06 Mn |
| Jun 30, 2023 | -8.37 Mn |
| Mar 31, 2023 | -6.53 Mn |
| Dec 31, 2022 | -9.47 Mn |
| Sep 30, 2022 | -8.32 Mn |
| Jun 30, 2022 | -8.67 Mn |
| Mar 31, 2022 | -8.94 Mn |
| Dec 31, 2021 | -9.13 Mn |
| Sep 30, 2021 | -16.81 Mn |
| Jun 30, 2021 | -12.61 Mn |
API Access
Larimar Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=LRMR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();